GSK's bird flu vacc on fast-track in Japan
GlaxoSmithKline's pre-pandemic vaccine for the H5N1 influenza virus strain has been given fast-track status by the Japanese Ministry of Health, Labor and Welfare, the Nikkei Weekly has reported.
The UK drug major will now continue with its Japanese development of the drug by moving into clinical trials as early as this year. Two other vaccines for H5N1 have already been approved in the country and are currently under production, including Swiss drug major Roche's Tamiflu (oseltamivir).
The Nikkei Weekly says that Japanese authorities have stockpiled enough of H5N1 vaccine for 20 million people, yet doubts regarding the effectiveness of the drugs has lead the authorities to encourage the production of as many different vaccines as possible.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze